Loading…

Cardiovascular and renal hemodynamic effects of intravenous infusions of the selective DA1 agonist, fenoldopam, used alone or in combination with dopamine and dobutamine

Fenoldopam (0.1 and 0.2 microgram/kg/min i.v.) was administered to pentobarbital-anesthetized dogs alone and combined with dopamine (DA) and dobutamine. Renal blood flow, heart rate, and mean arterial pressure were measured. Both dosages of fenoldopam increased renal blood flow without altering bloo...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 1988-11, Vol.78 (5), p.1310-1315
Main Authors: LASS, N. A, GLOCK, D, GOLDBERG, L. I
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c406t-e94179e09bd8750a13a1048ef5477c266db49191423887edf51200c3bc41f15d3
cites
container_end_page 1315
container_issue 5
container_start_page 1310
container_title Circulation (New York, N.Y.)
container_volume 78
creator LASS, N. A
GLOCK, D
GOLDBERG, L. I
description Fenoldopam (0.1 and 0.2 microgram/kg/min i.v.) was administered to pentobarbital-anesthetized dogs alone and combined with dopamine (DA) and dobutamine. Renal blood flow, heart rate, and mean arterial pressure were measured. Both dosages of fenoldopam increased renal blood flow without altering blood pressure, similar to the effects of DA (1 and 2 micrograms/kg/min). Administration of fenoldopam with only DA (1 microgram/kg/min) produced further increase in renal blood flow. After administration of phenoxybenzamine (15 mg/kg i.v.), DA produced significant increments in renal blood flow and reductions in renal vascular resistance when compared with experiments without phenoxybenzamine, suggesting even low dosages of DA exert alpha-adrenoceptor agonist activity. Dobutamine (2 and 4 micrograms/kg/min) increased renal blood flow about 37% of that produced by DA. Fenoldopam added to dobutamine produced similar increments in renal blood flow as DA. Fenoldopam did not affect the increase in cardiac contractile force produced by DA and dobutamine. Thus, fenoldopam alone or in combination with DA had no advantage over 2 and 4 micrograms/kg/min DA to further increase renal blood flow. In contrast, fenoldopam with dobutamine produced greater increments in cardiac contractile force than DA and equivalent increases in renal blood flow as DA.
doi_str_mv 10.1161/01.CIR.78.5.1310
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78482511</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78482511</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-e94179e09bd8750a13a1048ef5477c266db49191423887edf51200c3bc41f15d3</originalsourceid><addsrcrecordid>eNo9kUFv1DAQhS0EKkvhzgXJB8SpCZ7ETuJjtYW2UiUkBOfIsceskWMvdrKoP4l_iXe76skeve89zegR8h5YDdDBZwb19v573Q-1qKEF9oJsQDS84qKVL8mGMSarvm2a1-RNzr_L2LW9uCAXjWSN5LAh_7YqGRcPKuvVq0RVMDRhUJ7ucI7mMajZaYrWol4yjZa6sCR1wBDXXP52zS6Gk7DskGb0hXMHpDfXQNWvGFxerqgtuDdxr-YrumY0VPkYkMZUEqiO8-SCWkoO_euWHT2BrujHXUyc1uU0viWvrPIZ353fS_Lz65cf27vq4dvt_fb6odKcdUuF5axeIpOTGXrBFLQKGB_QCt73uuk6M3EJEnjTDkOPxgpoGNPtpDlYEKa9JJ-ecvcp_lkxL-PsskbvVcBy9NgPfGgEQAHZE6hTzDmhHffJzSo9jsDGYzsjg7G0UxyjGI_tFMuHc_Y6zWieDec6iv7xrJc-lLdJBe3yM9ZJyUUn2_-9n5oi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78482511</pqid></control><display><type>article</type><title>Cardiovascular and renal hemodynamic effects of intravenous infusions of the selective DA1 agonist, fenoldopam, used alone or in combination with dopamine and dobutamine</title><source>EZB Electronic Journals Library</source><creator>LASS, N. A ; GLOCK, D ; GOLDBERG, L. I</creator><creatorcontrib>LASS, N. A ; GLOCK, D ; GOLDBERG, L. I</creatorcontrib><description>Fenoldopam (0.1 and 0.2 microgram/kg/min i.v.) was administered to pentobarbital-anesthetized dogs alone and combined with dopamine (DA) and dobutamine. Renal blood flow, heart rate, and mean arterial pressure were measured. Both dosages of fenoldopam increased renal blood flow without altering blood pressure, similar to the effects of DA (1 and 2 micrograms/kg/min). Administration of fenoldopam with only DA (1 microgram/kg/min) produced further increase in renal blood flow. After administration of phenoxybenzamine (15 mg/kg i.v.), DA produced significant increments in renal blood flow and reductions in renal vascular resistance when compared with experiments without phenoxybenzamine, suggesting even low dosages of DA exert alpha-adrenoceptor agonist activity. Dobutamine (2 and 4 micrograms/kg/min) increased renal blood flow about 37% of that produced by DA. Fenoldopam added to dobutamine produced similar increments in renal blood flow as DA. Fenoldopam did not affect the increase in cardiac contractile force produced by DA and dobutamine. Thus, fenoldopam alone or in combination with DA had no advantage over 2 and 4 micrograms/kg/min DA to further increase renal blood flow. In contrast, fenoldopam with dobutamine produced greater increments in cardiac contractile force than DA and equivalent increases in renal blood flow as DA.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/01.CIR.78.5.1310</identifier><identifier>PMID: 2902941</identifier><identifier>CODEN: CIRCAZ</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams &amp; Wilkins</publisher><subject>Adrenergic alpha-Antagonists - pharmacology ; Animals ; Benzazepines - administration &amp; dosage ; Benzazepines - pharmacology ; Biological and medical sciences ; Blood Pressure - drug effects ; Cardiovascular system ; Dobutamine - pharmacology ; Dogs ; Dopamine - pharmacology ; Fenoldopam ; Infusions, Intravenous ; Medical sciences ; Miscellaneous ; Myocardial Contraction - drug effects ; Pharmacology. Drug treatments ; Phenoxybenzamine - pharmacology ; Renal Circulation - drug effects ; Vascular Resistance - drug effects</subject><ispartof>Circulation (New York, N.Y.), 1988-11, Vol.78 (5), p.1310-1315</ispartof><rights>1989 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-e94179e09bd8750a13a1048ef5477c266db49191423887edf51200c3bc41f15d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=6994569$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2902941$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LASS, N. A</creatorcontrib><creatorcontrib>GLOCK, D</creatorcontrib><creatorcontrib>GOLDBERG, L. I</creatorcontrib><title>Cardiovascular and renal hemodynamic effects of intravenous infusions of the selective DA1 agonist, fenoldopam, used alone or in combination with dopamine and dobutamine</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>Fenoldopam (0.1 and 0.2 microgram/kg/min i.v.) was administered to pentobarbital-anesthetized dogs alone and combined with dopamine (DA) and dobutamine. Renal blood flow, heart rate, and mean arterial pressure were measured. Both dosages of fenoldopam increased renal blood flow without altering blood pressure, similar to the effects of DA (1 and 2 micrograms/kg/min). Administration of fenoldopam with only DA (1 microgram/kg/min) produced further increase in renal blood flow. After administration of phenoxybenzamine (15 mg/kg i.v.), DA produced significant increments in renal blood flow and reductions in renal vascular resistance when compared with experiments without phenoxybenzamine, suggesting even low dosages of DA exert alpha-adrenoceptor agonist activity. Dobutamine (2 and 4 micrograms/kg/min) increased renal blood flow about 37% of that produced by DA. Fenoldopam added to dobutamine produced similar increments in renal blood flow as DA. Fenoldopam did not affect the increase in cardiac contractile force produced by DA and dobutamine. Thus, fenoldopam alone or in combination with DA had no advantage over 2 and 4 micrograms/kg/min DA to further increase renal blood flow. In contrast, fenoldopam with dobutamine produced greater increments in cardiac contractile force than DA and equivalent increases in renal blood flow as DA.</description><subject>Adrenergic alpha-Antagonists - pharmacology</subject><subject>Animals</subject><subject>Benzazepines - administration &amp; dosage</subject><subject>Benzazepines - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Cardiovascular system</subject><subject>Dobutamine - pharmacology</subject><subject>Dogs</subject><subject>Dopamine - pharmacology</subject><subject>Fenoldopam</subject><subject>Infusions, Intravenous</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Myocardial Contraction - drug effects</subject><subject>Pharmacology. Drug treatments</subject><subject>Phenoxybenzamine - pharmacology</subject><subject>Renal Circulation - drug effects</subject><subject>Vascular Resistance - drug effects</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1988</creationdate><recordtype>article</recordtype><recordid>eNo9kUFv1DAQhS0EKkvhzgXJB8SpCZ7ETuJjtYW2UiUkBOfIsceskWMvdrKoP4l_iXe76skeve89zegR8h5YDdDBZwb19v573Q-1qKEF9oJsQDS84qKVL8mGMSarvm2a1-RNzr_L2LW9uCAXjWSN5LAh_7YqGRcPKuvVq0RVMDRhUJ7ucI7mMajZaYrWol4yjZa6sCR1wBDXXP52zS6Gk7DskGb0hXMHpDfXQNWvGFxerqgtuDdxr-YrumY0VPkYkMZUEqiO8-SCWkoO_euWHT2BrujHXUyc1uU0viWvrPIZ353fS_Lz65cf27vq4dvt_fb6odKcdUuF5axeIpOTGXrBFLQKGB_QCt73uuk6M3EJEnjTDkOPxgpoGNPtpDlYEKa9JJ-ecvcp_lkxL-PsskbvVcBy9NgPfGgEQAHZE6hTzDmhHffJzSo9jsDGYzsjg7G0UxyjGI_tFMuHc_Y6zWieDec6iv7xrJc-lLdJBe3yM9ZJyUUn2_-9n5oi</recordid><startdate>19881101</startdate><enddate>19881101</enddate><creator>LASS, N. A</creator><creator>GLOCK, D</creator><creator>GOLDBERG, L. I</creator><general>Lippincott Williams &amp; Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19881101</creationdate><title>Cardiovascular and renal hemodynamic effects of intravenous infusions of the selective DA1 agonist, fenoldopam, used alone or in combination with dopamine and dobutamine</title><author>LASS, N. A ; GLOCK, D ; GOLDBERG, L. I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-e94179e09bd8750a13a1048ef5477c266db49191423887edf51200c3bc41f15d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1988</creationdate><topic>Adrenergic alpha-Antagonists - pharmacology</topic><topic>Animals</topic><topic>Benzazepines - administration &amp; dosage</topic><topic>Benzazepines - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Cardiovascular system</topic><topic>Dobutamine - pharmacology</topic><topic>Dogs</topic><topic>Dopamine - pharmacology</topic><topic>Fenoldopam</topic><topic>Infusions, Intravenous</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Myocardial Contraction - drug effects</topic><topic>Pharmacology. Drug treatments</topic><topic>Phenoxybenzamine - pharmacology</topic><topic>Renal Circulation - drug effects</topic><topic>Vascular Resistance - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LASS, N. A</creatorcontrib><creatorcontrib>GLOCK, D</creatorcontrib><creatorcontrib>GOLDBERG, L. I</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LASS, N. A</au><au>GLOCK, D</au><au>GOLDBERG, L. I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardiovascular and renal hemodynamic effects of intravenous infusions of the selective DA1 agonist, fenoldopam, used alone or in combination with dopamine and dobutamine</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>1988-11-01</date><risdate>1988</risdate><volume>78</volume><issue>5</issue><spage>1310</spage><epage>1315</epage><pages>1310-1315</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><coden>CIRCAZ</coden><abstract>Fenoldopam (0.1 and 0.2 microgram/kg/min i.v.) was administered to pentobarbital-anesthetized dogs alone and combined with dopamine (DA) and dobutamine. Renal blood flow, heart rate, and mean arterial pressure were measured. Both dosages of fenoldopam increased renal blood flow without altering blood pressure, similar to the effects of DA (1 and 2 micrograms/kg/min). Administration of fenoldopam with only DA (1 microgram/kg/min) produced further increase in renal blood flow. After administration of phenoxybenzamine (15 mg/kg i.v.), DA produced significant increments in renal blood flow and reductions in renal vascular resistance when compared with experiments without phenoxybenzamine, suggesting even low dosages of DA exert alpha-adrenoceptor agonist activity. Dobutamine (2 and 4 micrograms/kg/min) increased renal blood flow about 37% of that produced by DA. Fenoldopam added to dobutamine produced similar increments in renal blood flow as DA. Fenoldopam did not affect the increase in cardiac contractile force produced by DA and dobutamine. Thus, fenoldopam alone or in combination with DA had no advantage over 2 and 4 micrograms/kg/min DA to further increase renal blood flow. In contrast, fenoldopam with dobutamine produced greater increments in cardiac contractile force than DA and equivalent increases in renal blood flow as DA.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>2902941</pmid><doi>10.1161/01.CIR.78.5.1310</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0009-7322
ispartof Circulation (New York, N.Y.), 1988-11, Vol.78 (5), p.1310-1315
issn 0009-7322
1524-4539
language eng
recordid cdi_proquest_miscellaneous_78482511
source EZB Electronic Journals Library
subjects Adrenergic alpha-Antagonists - pharmacology
Animals
Benzazepines - administration & dosage
Benzazepines - pharmacology
Biological and medical sciences
Blood Pressure - drug effects
Cardiovascular system
Dobutamine - pharmacology
Dogs
Dopamine - pharmacology
Fenoldopam
Infusions, Intravenous
Medical sciences
Miscellaneous
Myocardial Contraction - drug effects
Pharmacology. Drug treatments
Phenoxybenzamine - pharmacology
Renal Circulation - drug effects
Vascular Resistance - drug effects
title Cardiovascular and renal hemodynamic effects of intravenous infusions of the selective DA1 agonist, fenoldopam, used alone or in combination with dopamine and dobutamine
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T19%3A27%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardiovascular%20and%20renal%20hemodynamic%20effects%20of%20intravenous%20infusions%20of%20the%20selective%20DA1%20agonist,%20fenoldopam,%20used%20alone%20or%20in%20combination%20with%20dopamine%20and%20dobutamine&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=LASS,%20N.%20A&rft.date=1988-11-01&rft.volume=78&rft.issue=5&rft.spage=1310&rft.epage=1315&rft.pages=1310-1315&rft.issn=0009-7322&rft.eissn=1524-4539&rft.coden=CIRCAZ&rft_id=info:doi/10.1161/01.CIR.78.5.1310&rft_dat=%3Cproquest_cross%3E78482511%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c406t-e94179e09bd8750a13a1048ef5477c266db49191423887edf51200c3bc41f15d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=78482511&rft_id=info:pmid/2902941&rfr_iscdi=true